Supreme Court Justice Samuel Alito temporarily blocked on Monday an appeals court ruling that barred abortion pills from being sold online and transported to patients via mail, granting a reprieve to medication abortion access while higher courts weigh in.
The ruling at issue came Friday from the U.S. Court of Appeals for the 5th Circuit, which had restored an in-person screening requirement for access to mifepristone, one of two drugs used in medication abortions. Two drugmakers that manufacture and distribute mifepristone petitioned the Supreme Court to halt the lower court decision, arguing it created "nationwide chaos" by disrupting established distribution channels.
Alito, who handles emergency appeals from the 5th Circuit as the assigned justice, issued an administrative stay pausing the appellate ruling through 5 p.m. on May 11. The pause gives the full Supreme Court time to consider whether to grant longer-term relief while litigation continues.
What the Left Is Saying
Reproductive rights advocates have long defended broad access to medication abortion, arguing that in-person requirements create unnecessary barriers for patients, particularly those in rural areas or with limited mobility. Groups such as Planned Parenthood and the American Civil Liberties Union have argued that mail-order options expand timely access to care within the window permitted by law.
Abortion rights supporters contend that restricting mifepristone distribution disrupts a safe, FDA-approved medication that has been used by millions of Americans since its approval in 2000. They maintain that courts should not override regulatory determinations made by scientific and medical experts at the FDA regarding the drug's safety profile when used under existing protocols.
What the Right Is Saying
Anti-abortion advocates have welcomed court challenges to expanded abortion pill access, arguing that medication abortions carry medical risks that warrant clinical oversight. Organizations such as Students for Life of America and SBA List have supported restrictions requiring in-person evaluations, arguing that patients deserve face-to-face consultation with physicians before receiving abortion-inducing drugs.
Conservative legal groups contend that courts have properly scrutinized the FDA's regulatory process and that federal judges are within their authority to review agency actions. Groups filing briefs in support of restrictions have pointed to concerns about telemedicine prescriptions for abortion medications without corresponding physical examinations.
What the Numbers Show
Mifepristone was approved by the Food and Drug Administration in 2000 as safe and effective when used according to the agency's protocols. The medication works in conjunction with misoprostol in a two-drug regimen that accounts for more than half of all abortions performed in the United States, according to data from the Guttmacher Institute.
The FDA temporarily allowed mail-order distribution of mifepristone during the COVID-19 pandemic, making permanent that flexibility in 2021. The Supreme Court's 2022 Dobbs decision overturning Roe v. Wade elevated the significance of medication abortion access as states with abortion bans sought to limit pharmaceutical options alongside procedural restrictions.
The Bottom Line
The administrative stay preserves the status quo for mifepristone distribution through May 11, but the legal battle is far from resolved. The full Supreme Court will decide whether to extend relief while litigation proceeds through federal courts, a process that could take months or years depending on how quickly cases move.
What happens next depends largely on how the justices rule on the emergency petitions and ultimately on the merits of underlying challenges to FDA authority over mifepristone. Advocates on both sides say the case could have implications extending well beyond abortion, potentially reshaping the relationship between federal regulatory agencies and the courts.